Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion.

Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period. Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces.

Pick a time frame -- year to date, last 12 months, last three years, last five years, or last 10 years. Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period.

Sickle Cell Disease Market Insight, Epidemiology And Market Forecast - 2034The sickle cell disease treatment market is experiencing signific ...

Pfizer has experienced disappointing product and pipeline setbacks as well. It withdrew sickle cell disease therapy Oxbryta from the market last year after concluding that the benefits no longer ...

The Sickle Cell Disease Treatment Market is expected to reach at a CAGR of 15.8% during the forecast period 2025-2033. The Sickle Cell Disease Treatment Market is growing due to rising disease ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for ...

I'm unvaxxed but for $20 mil I'd tell everyone to get the shot. Sorry not sorry. — Harry Berries (@MrHarryBerries) June 18, 2025 “Why does Pfizer need to pay Travis Kelce $20m,” asked ...